More than three decades ago, as a test for the amphipathic helix theory, an 18 amino acid residue peptide and its analogs were designed with no sequence homology to any of the exchangeable apolipoproteins. Based on the apolipoprotein A-I (the major protein component of high density lipoproteins, HDL) mimicking properties, they were termed as ApoA-I mimicking peptides. Several laboratories around the world started studying such de novo-designed peptides for their antiatherogenic properties. The present chapter describes the efforts in bringing these peptides as therapeutic agents for atherosclerosis and several lipid-mediated disorders.
Keywords: Apolipoprotein mimetic peptides; Atherosclerosis; HDL apoA-I; LDL; apoE.
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.